Xeris Biopharma Has Announced the Initiation of a Phase 2 Clinical Study for Its Investigational Subcutaneous Levothyroxine in Patients with Hypothyroidism

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company focused on enhancing patients’ well-being through the development and commercialization of innovative products across various therapeutic areas, has reported the dosing of the first participant in a Phase 2 clinical study. This multi-centre, open-label study aims to evaluate the efficacy as a treatment for adults with hypothyroidism.

A target dose conversion factor from stably dosed oral levothyroxine to levothyroxine sodium in patients with hypothyroidism is being determined in the Phase 2 study, as well as the safety and tolerability of the drug following once-weekly subcutaneous injections. Screening, Titration Period (2 to 8 weeks), and Maintenance Period (4 weeks) are all included in this study. Throughout the Maintenance Period, a subset of patients will participate in a pharmacokinetic sub-study.


Source: Xerisbiopharma.com